The Experimental and Basic Sciences core of SERI comprises of all the research laboratory space and core equipment contained therein that facilitate and support the translational and basic ocular disease research within SERI. This research platform provides the core facilities available for all SERI researchers engaged in wet or bench laboratory research. The Experimental & Basic Sciences Research Platform is further divided into three separate facilities.
1. Experimental Microscopy, Molecular & Cell Biology
Head: Assoc Prof Wang Xiaomeng
2. Proteomics
Head: Assoc Prof Wang Xiaomeng
3. Translational Ophthalmic Pathology & Immunology
Head: Dr Anita Chan
(1) Experimental Microscopy, Molecular & Cell Biology includes all the tissue culture and -80 degree freezer rooms, laboratories dedicated to electrophysiology, chemistry and microbiology, as well as 33 general lab benches. Both specialised cell biology and general core lab equipment are part of this facility. This platform is supported by two laboratory managers who oversee daily laboratory operations, procure equipment, monitor utilisation of space, update risk assessments and ensure that biological and general workplace safety are in compliance with the rules and regulations of the SingHealth Institutional Biosafety Committee (SHSIBC).
(2) The Proteomics Facility, housed within a micro-analytical laboratory, is equipped with 2 HPLCs (nano- and high-flow) and 2 mass spectrometers (high-resolution TripleTOF and triple quadrupole) for proteomics, metabolomics and drug analyses. This facility provides 25 types of services, including gel protein identification, affinity purification of complex samples, relative/absolute quantitative proteomic analysis, identification/quantification of post-translational modifications, biomarker discovery/ validation, untargeted/targeted metabolomics, and pharmacokinetics/drug quantitation. New proteomics/metabolomics technologies to access the frontier “Omics” technologies are being developed.
(3) The Translational Ophthalmic Pathology & Immunology Facility works in synergy with the Experimental Microscopy and Imaging Facility to provide specialised non-routine histopathology services involving ophthalmic tissues. This facility is led by a trained ophthalmic pathologist, Dr Anita Chan. Non-routine histological services include but are not limited to specialised techniques for tissue processing for transmission electron microscopy, multiplexed immunohistochemistry and preparation of ocular microvasculature and retinal tissue whole mounts.
The Translational Ophthalmic Pathology & Immunology as well as The Experimental Microscopy and Imaging Facilities interact with the Department of Anatomical Pathology of the Singapore General Hospital and the Advanced Bio-imaging Core. They provide SERI researchers with access to a variety of advanced imaging equipment, as well as specialized services that help keep them abreast with advancing technology in this area.
Overview
The Proteomics Laboratory is a core platform in SERI and provides expertise and instrumentation in cutting-edge proteomics and metabolomics research. Established in 2004, the Ocular Proteomics Laboratory focuses on the application of proteomics to clinical samples from the eye to find new biomarkers and understand the disease. Additionally, we collaborate with other research groups within SERI and SNEC. We offer a broad range of proteomics/metabolomics and biological mass spectrometry (MS) services, including protein identification, quantitative proteomics (iTRAQ, high resolution – MRM, SWATH, etc.), characterisation of post-translational modifications (PTMs), MS-based non-targeted and targeted metabolomics and drug analysis. Recently, we have been asked to participate in the Human Proteome Organisation (HUPO) Eye Proteome project, which aims to establish a human eye proteome database.
Facilities
Capabilities
Projects
One of our focuses is on tear fluid proteomics and metabolomics. We believe that tear fluid is a useful source for discovering biomarkers associated with the various components of the lacrimal functional unit, because of the close relationship of tears to the disease sites. Recent studies by our group showed that more than 1500 proteins and 60 small molecule metabolites were identified in healthy human tears using the latest proteomics and metabolomics technology. This comprehensive tear composition repertoire can be served as a background for future biomarker research of ocular diseases.
The current biomarker research projects which use tears as the source are:
Other important proteomics/metabolomics projects include:
Publications
Head
Assoc Prof Wang Xiaomeng
Experimental Microscopy, Molecular & Cell Biology
Overview
The Experimental Microscopy, Molecular & Cell Biology Research Platform provides the infrastructure and a range of essential and sophisticated core equipment to facilitate researchers in Singapore Eye Research Institute/Singapore National Eye Centre in their basic to advanced molecular and cell biology studies.
Facilities
Our laboratory space occupies two floors, on the 11th and 12th floors of The Academia. There are 33 general laboratory benches as well as rooms dedicated to the following:
Core equipment includes:
Manpower
This research platform is managed by the SERI laboratory administration team and supported by scientists, research officers and laboratory executives to ensure optimal performance of all facilities and equipment. We comply with the rules and regulations of the SingHealth Institutional Biosafety Committee (SHSIBC).
Projects
Molecular and cellular experimentation is fundamental to understanding the mechanisms of eye diseases, as well as drugs for therapy. The projects facilitated by this platform are multidisciplinary, diverse and vary in both breadth and depth. Besides supporting experimental research, this platform also offers assistance for assessing other resources within the SingHealth campus and beyond. We collaborate extensively with other academic institutions within Singapore. We also welcome collaboration with industry partners interested in eye-related research or the exploration of innovative molecular and cell technologies. Our industry collaborators include AYOXXA Biosystems (Cologne, Germany) and Santen Pharmaceutical Co., Ltd. (Osaka, Japan).
Examples of ongoing research areas include:
Head
Assoc Prof Wang Xiaomeng
Translational Ophthalmic Pathology & Immunology
Overview
The Translational Ophthalmic Pathology & Immunology Research Platform is a core platform that specializes in molecular pathology for the study of the pathology of ocular disorders. In our laboratory we have the latest DEPArray NXt © machine which has the capacity to sort single cells from fresh and fixed tissues, as well as paraffin embedded tissues for further downstream analysis. Tissues may be liquid based or solid tissue. This technology is superior to routine flow cytometry as it is able to handle single cells. The major disadvantage in working with ocular tissues is the small specimen size and limited cellular quantity. This technology is crucial for advancing molecular capabilities in our ophthalmic related research.
The research platform is led by Dr Anita Chan who is a practicing ophthalmologist, as well as a trained ophthalmic pathologist. In our team, we have expertise in analyzing human and animal related histology for clinical and research studies respectively.
In addition to molecular pathology, we also offer advance histological services including:
Our research platform works closely with the other core units in SERI (ocular genetics, proteomics, translational pre-clinical model research platform, as well as the microscopy imaging unit) to provide a comprehensive approach for ophthalmic research studies.
Projects
Head
Dr Anita Chan (PI)
Team members
Collaborators